RNAi News | July 17, 2008

Search the GenomeWeb Intelligence Network

Advanced Search

RNAi News
GenomeWeb News Premium Content
Existing subscribers login here.
New to RNAi News? For a trial subscription click here.

Volume 6 - Number 29 | July 17, 2008

Subscriber Login
Subscribe to RNAi News
Site Licenses
RSS Feed
Archives

In This Week's Issue

Cellumen to Focus on Discovery Toxicology After Spin Out of Personalized Med Unit

Vala Nears End of Grant to Develop hESC Differentiation Assay

WUSTL Spin-Out PixelEXX Lands $250K in Seed Funding to Develop Cell-Imaging Array

Sanofi-Aventis Deutschland, Dana Farber Cancer Institute Awarded US Patents

MDS, National Institute for Environmental Health Sciences, National Human Genome Research Institute, National Institute of Mental Health

Alan Fletcher, Charles Blitzer

Features

Quark Taps Glaucoma Drug to Be Its First Novel RNAi Agent, CEO Speaks Out on Silence
Quark’s investigational glaucoma treatment would be its first completely proprietary siRNA drug, which is expected to help the company avoid the kind of confusion it said has plagued its other clinical candidates, which incorporate chemical structures licensed from other firms.

Opko, Frost Group Ask Court to Dismiss Conspiracy Charges in Suit Filed by Rival
Opko, responding to a lawsuit by rival Ophthalmic Imaging Systems charging it with conspiring with a former employee to interfere with OIS’ business activities, told the judge that the activities were part of standard business practices. It also said OIS’ case is weak because it “relies on secondary theories of liability.”

With Phase I SBIR Grant, AM Biotechnologies Looks to Apply Thioaptamer Tech to siRNAs
The $199,999 award from the National Institute of General Medical Sciences will help the company develop its core thioaptamer technology for synthesizing modified RNA oligonucleotides, including siRNAs.

IP Update

USPTO Publishes One Patent, Two Patent Applications Related to RNAi

Strands

Novartis, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Silence Therapeutics

People in the News

Vin Miles, Jeff Vick, Iain Ross, Jeremy Curnock Cook